Anterior Gradient-3: a novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft models.
about
Generalized portrait of cancer metabolic pathways inferred from a list of genes overexpressed in cancerDevelopment of a fluorescent monoclonal antibody-based assay to measure the allosteric effects of synthetic peptides on self-oligomerization of AGR2 protein.AGR3 in breast cancer: prognostic impact and suitable serum-based biomarker for early cancer detection.Anterior gradient protein 3 is associated with less aggressive tumors and better outcome of breast cancer patients.The estrogen-regulated anterior gradient 2 (AGR2) protein in breast cancer: a potential drug target and biomarkerEmerging roles for the pro-oncogenic anterior gradient-2 in cancer development.Engineering a synthetic cell panel to identify signalling components reprogrammed by the cell growth regulator anterior gradient-2.The secreted factor Ag1 missing in higher vertebrates regulates fins regeneration in Danio rerio.Agr genes, missing in amniotes, are involved in the body appendages regeneration in frog tadpoles.Emerging roles of protein disulfide isomerase in cancer.Anterior gradient protein 2 (AGR2) is an independent prognostic factor in ovarian high-grade serous carcinoma.Expression of protein disulfide isomerase family members correlates with tumor progression and patient survival in ovarian cancer.The sequence-specific peptide-binding activity of the protein sulfide isomerase AGR2 directs its' stable binding to the oncogenic receptor EpCAM.Differential Gene Expression in Ductal Carcinoma In Situ of the Breast Based on ERBB2 Status.Anterior gradient 2 and 3--two prototype androgen-responsive genes transcriptionally upregulated by androgens and by oestrogens in prostate cancer cells.
P2860
Q34176623-F7DDCC89-EB77-4E9B-8ABA-50C85F313F69Q34777828-58796521-A92F-4A87-A9D6-B491E1B1C2F8Q35432936-BD5529F1-5136-4D27-8AF2-55780BCF0E4CQ35799421-D71CF924-6EA3-4DC5-BA3B-DF88945F0DF7Q36903188-B64F8BEA-C217-40C3-AF1C-B684AFCBBE7EQ38040355-249C3BAD-A297-4A04-9B5C-85572C509E8AQ39006763-71FEC0A0-EC11-416E-BE9D-88B483AD7BBFQ41513761-210CF595-3424-4386-A127-164C234C58A1Q41985690-9E878566-6F49-47A7-92A1-394BDFCE89ECQ42357758-05D9FDC0-22F7-4055-AA08-C10C626D7322Q44677297-05725948-3954-47EA-8170-DB4BBEB69061Q47098483-CA4A96FB-C820-4081-BAFB-1533B5013F10Q50020631-BF65974B-E7B4-4BF0-B9CB-66E21CB9D3BCQ51145791-4EBB8D3A-6DDB-4F98-A1DE-D5FFB39CC562Q53259961-E78C5A1C-451F-4B86-A555-80FAB5D3285D
P2860
Anterior Gradient-3: a novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft models.
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Anterior Gradient-3: a novel b ...... esistance in xenograft models.
@ast
Anterior Gradient-3: a novel b ...... esistance in xenograft models.
@en
Anterior Gradient-3: a novel b ...... esistance in xenograft models.
@nl
type
label
Anterior Gradient-3: a novel b ...... esistance in xenograft models.
@ast
Anterior Gradient-3: a novel b ...... esistance in xenograft models.
@en
Anterior Gradient-3: a novel b ...... esistance in xenograft models.
@nl
prefLabel
Anterior Gradient-3: a novel b ...... esistance in xenograft models.
@ast
Anterior Gradient-3: a novel b ...... esistance in xenograft models.
@en
Anterior Gradient-3: a novel b ...... esistance in xenograft models.
@nl
P2093
P921
P1476
Anterior Gradient-3: a novel b ...... esistance in xenograft models.
@en
P2093
Borek Vojtesek
Caroline O Michie
Charlie Gourley
Euan Murray
Jacqueline Howie
Larry Hayward
Magdalena M Maslon
Nicola J MacLaine
Pavla Bouchalova
Roman Hrstka
P356
10.1016/J.JIM.2012.01.013
P577
2012-02-15T00:00:00Z